All Oncology articles – Page 8
-
NewsHow antibody-drug conjugates are improving gynaecological cancer outcomes
Antibody-drug conjugates (ADCs) are emerging as a breakthrough in the fight against gynaecological cancers, offering targeted treatment for cervical, ovarian and uterine tumours.
-
ArticleWhy first-void urine could potentially change the future of HPV screening
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
-
NewsTRβ receptor could be key to slowing prostate cancer
A thyroid hormone receptor may play a key role in prostate cancer growth, offering a potential new target for treating aggressive forms of the disease.
-
NewsProtein FSP1 found to help melanoma survive in lymph nodes
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer cells spreading to lymph nodes depend on a protein called FSP1 to avoid cell death.
-
NewsSugar-coated tumours: a new target for pancreatic cancer
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows tumour growth.
-
ArticleCD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
-
ArticleWhat’s changing in cancer drug discovery – and why it matters now
Take part in a live Q&A with oncology experts as they explore the scientific advances driving cancer drug discovery.
-
NewsExisting nerve pain drugs may help stop bone cancer spread
Scientists have discovered that two existing pain medications – bupivacaine and rimegepant – may not only relieve the severe pain caused by osteosarcoma but also slow the disease’s growth.
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
ArticleFrom war rooms to launch rooms: how AI is changing the game
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
-
NewsHow nanocarriers and VLPs are uniting to fight cancer
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
-
NewsTargeting EZH2 may prevent triple-negative breast cancer spread
A new study has revealed that the enzyme EZH2 triggers abnormal cell division that fuels metastasis, and blocking this enzyme with existing drugs could restore normal cell behaviour to stop cancer from spreading.
-
NewsCloneSeq-SV: new blood test tracks ovarian cancer recurrence
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
-
NewsHypoxia and EUDAL: the hidden drivers of oral cancer survival
A newly discovered RNA molecule, EUDAL, helps oral cancers survive chemotherapy by keeping a key growth protein permanently active. Researchers say targeting EUDAL could predict resistance and improve treatment outcomes.
-
NewsSenolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
-
NewsTiny models, powerful insights: how organoids are driving precision oncology
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
-
NewsProtecting bones from cancer damage: targeting the UPR pathway
New research highlights how cancer hijacks the unfolded protein response (UPR) in bone cells – potentially allowing for the development of therapies that target this pathway to prevent fractures.
-
NewsGlioblastoma treatment boosted by new drug combination strategy
Researchers in China have discovered how glioblastoma adapts to low-oxygen conditions – revealing a new treatment strategy that combines an orphan drug with standard chemotherapy to overcome resistance.
-
ArticleThe science behind the systematic discovery of molecular glues
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
-
ArticleOvercoming barriers to oncology combination therapies in the UK and EU
Colleagues at IQVIA discuss ways to expedite positive HTA outcomes for innovative combination therapies, alleviating the bottlenecks inherent in the current system.